AbCellera Biologics Inc.
ABCLUS売上高
$75M
百万USD
営業利益
$-217M
百万USD
純利益
$-146M
百万USD
ROE
-15.1%
最新FY
EPS
$-0.49
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $203M | $117M | $0.37 |
| FY2021 | Q2 | $28M | $-2M | $-0.01 |
| FY2021 | Q3 | $6M | $-21M | $-0.08 |
| FY2021 | FY | $375M | $153M | $0.48 |
| FY2022 | Q1 | $317M | $169M | $0.54 |
| FY2022 | Q2 | $46M | $-7M | $-0.02 |
| FY2022 | Q3 | $101M | $27M | $0.08 |
| FY2022 | FY | $485M | $159M | $0.50 |
| FY2023 | Q1 | $12M | $-40M | $-0.14 |
| FY2023 | Q2 | $10M | $-31M | $-0.11 |
| FY2023 | Q3 | $7M | $-29M | $-0.10 |
| FY2023 | FY | $38M | $-146M | $-0.51 |
| FY2024 | Q1 | $10M | $-41M | $-0.14 |
| FY2024 | Q2 | $7M | $-37M | $-0.13 |
| FY2024 | Q3 | $7M | $-51M | $-0.17 |
| FY2024 | FY | $29M | $-163M | $-0.55 |
| FY2025 | Q1 | $4M | $-46M | $-0.15 |
| FY2025 | Q2 | $17M | $-35M | $-0.12 |
| FY2025 | Q3 | $9M | $-57M | $-0.19 |
| FY2025 | FY | $75M | $-146M | $-0.49 |
| FY2026 | Q1 | $8M | $-43M | $-0.14 |
財務データ
| 指標 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| 売上高 | $375M | $485M | $38M | $29M | $75M |
| 営業利益 | $204M | $217M | $-237M | $-315M | $-217M |
| 純利益 | $153M | $159M | $-146M | $-163M | $-146M |
| 総資産 | $1.3B | $1.5B | $1.5B | $1.4B | $1.4B |
| 純資産 | - | - | - | - | - |
| 自己資本 | $1.0B | $1.2B | $1.2B | $1.1B | $967M |
| 営業CF | $245M | $277M | $-44M | $-109M | $-131M |
| EPS | $0.48 | $0.50 | $-0.51 | $-0.55 | $-0.49 |
| BPS | $3.61 | $4.29 | $3.94 | $3.54 | $3.19 |
| ROE | 15.0% | 12.9% | -12.7% | -15.4% | -15.1% |